Referred to the House Committee on Energy and Commerce.
Requires federal agencies to include in funding agreements and patents/licenses a requirement that biomedical products or services developed with federal support be sold at a “reasonable” price as determined by HHS. Prohibits U.S. prices above a reference price based on Canada plus six high-income OECD countries, allows HHS rulemaking for additional price controls, mandates public reporting of trial costs, federal subsidies, and county-level revenues, and permits waivers only after public notice, hearing, and economic analysis.
Progressives emphasize affordability and taxpayer return on federally funded R&D
Relative to its intended legislative type, this bill creates a substantive legal obligation tying prices of biomedical products developed with federal support to a Secretary-determined reasonableness standard and a specified international reference-price framework, and it includes transparency and waiver procedures.
Requires federal agencies to include in funding agreements and patents/licenses a requirement that biomedical products or services developed with federal support be sold at a “reasonable” price as determined by HHS.
Prohibits U.S. prices above a reference price based on Canada plus six high-income OECD countries, allows HHS rulemaking for additional price controls, mandates public reporting of trial costs, federal subsidies, and county-level revenues, and permits waivers only after public notice, hearing, and economic analysis.
Broad federal pricing mandates tied to research funding are politically and legally contentious, inviting industry resistance and complex rulemaking.
Relative to its intended legislative type, this bill creates a substantive legal obligation tying prices of biomedical products developed with federal support to a Secretary-determined reasonableness standard and a specified international reference-price framework, and it includes transparency and waiver procedures. The bill relies heavily on delegated regulatory action by the Secretary of HHS and on federal agencies to incorporate contractual clauses, but it omits several implementation and resourcing particulars expected for a nationwide substantive reform.
Progressives emphasize affordability and taxpayer return on federally funded R&D
These are examples from the analysis, not a ranked list of the most-affected groups.
Progressives emphasize affordability and taxpayer return on federally funded R&D
Likely supportive because the bill ties taxpayer-funded research to taxpayer protections, affordability, and transparency.
Sees it as a way to reduce U.S. drug costs and increase public return on federal investments while keeping exemptions limited and public.
Cautiously supportive but pragmatic about tradeoffs: favors taxpayer accountability and transparency, but worries about innovation incentives, administrative complexity, and legal challenges.
Would seek clear standards and implementation funding.
Likely opposed, viewing the bill as government overreach that imposes price controls and regulatory uncertainty on private R&D.
Concerned it will chill investment, reduce licensing, and harm domestic biopharma competitiveness.
Reached or meaningfully advanced
Reached or meaningfully advanced
Still ahead
Still ahead
Still ahead
Broad federal pricing mandates tied to research funding are politically and legally contentious, inviting industry resistance and complex rulemaking.
The bill has not accumulated any surfaced votes yet.
Progressives emphasize affordability and taxpayer return on federally funded R&D
Broad federal pricing mandates tied to research funding are politically and legally contentious, inviting industry resistance and complex r…
Relative to its intended legislative type, this bill creates a substantive legal obligation tying prices of biomedical products developed with federal support to a Secretary-determined reasonableness standard and a spec…
Go beyond the headline summary with full stakeholder mapping, legislative design analysis, passage barriers, and lens-by-lens tradeoff breakdowns.